Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Short term Debt (2016 - 2018)

Historic Short term Debt for Niagen Bioscience (NAGE) over the last 3 years, with Q4 2018 value amounting to $137000.0.

  • Niagen Bioscience's Short term Debt fell 5580.65% to $137000.0 in Q4 2018 from the same period last year, while for Dec 2018 it was $137000.0, marking a year-over-year decrease of 5580.65%. This contributed to the annual value of $137000.0 for FY2018, which is 5580.65% down from last year.
  • Latest data reveals that Niagen Bioscience reported Short term Debt of $137000.0 as of Q4 2018, which was down 5580.65% from $310000.0 recorded in Q4 2017.
  • In the past 5 years, Niagen Bioscience's Short term Debt registered a high of $1.5 million during Q1 2016, and its lowest value of $137000.0 during Q4 2018.
  • In the last 3 years, Niagen Bioscience's Short term Debt had a median value of $327000.0 in 2016 and averaged $579894.5.
  • Per our database at Business Quant, Niagen Bioscience's Short term Debt crashed by 7749.54% in 2016 and then plummeted by 988.37% in 2017.
  • Over the past 3 years, Niagen Bioscience's Short term Debt (Quarter) stood at $344000.0 in 2016, then fell by 9.88% to $310000.0 in 2017, then tumbled by 55.81% to $137000.0 in 2018.
  • Its Short term Debt was $137000.0 in Q4 2018, compared to $310000.0 in Q4 2017 and $344000.0 in Q4 2016.